Abstract: A method for producing a hydrogenated polymer composition including a hydrogenated conjugated diene modified polymer that has a boron-containing functional group, the method including: (1) anionically polymerizing a monomer including a conjugated diene in the presence of a reactive metal or reactive metal compound capable of causing anionic polymerization to produce a reactive terminal polymer (Z); (2) reacting the reactive terminal polymer (Z) obtained in (1) with a boric acid compound that has at least two partial structures represented by B—O—R (I), and in which at least one R bonded to an oxygen atom in the partial structure (I) has a Taft's steric parameter Es value of ?0.30 or less to obtain an unhydrogenated conjugated diene modified polymer having a boron-containing functional group; and (3) hydrogenating at least some of carbon-carbon double bonds contained in conjugated diene units included in the unhydrogenated conjugated diene modified polymer obtained in (2).

Abstract: Disclosed is a method for detecting an antigen-specific activated T cell comprising: acquiring first information on a particle size and second information on a T cell activation marker for a first measurement sample prepared by mixing in vitro a first specimen separated from a biological sample containing a T cell and an antigen-presenting cell and an antigen reagent containing a predetermined antigen, by measuring the first measurement sample with a flow cytometer; acquiring the first information and the second information for a second measurement sample prepared from a second specimen separated from the biological sample and not containing the antigen reagent, by measuring the second measurement sample with the flow cytometer; detecting a target particle in the first measurement sample based on the first information and the second information on the first measurement sample, and detecting a background particle in the second measurement sample based on the first information and the second information on the

Abstract: A novel use of agonist to PD-1 is developed. Provided is a pharmaceutical composition for treating or preventing Th2-mediated diseases, the composition comprising an effective amount of a PD-1 agonist.

Abstract: A method is provided herein to increase an immune response to an antigen. The method includes administering an agent that inhibits extracellular adenosine or inhibits adenosine receptors. Also disclosed are methods to increase the efficacy of a vaccine and to increase an immune response to a tumor antigen or immune cell-mediated tumor destruction.

Abstract: A method is provided herein to increase an immune response to an antigen. The method includes administering an agent that inhibits extracellular adenosine or inhibits adenosine receptors. Also disclosed are methods to increase the efficacy of a vaccine and to increase an immune response to a tumor antigen or immune cell-mediated tumor destruction.

Abstract: A method is provided herein to increase an immune response to an antigen. The method includes administering an agent that inhibits extracellular adenosine or inhibits adenosine receptors. Also disclosed are methods to increase the efficacy of a vaccine and to increase an immune response to a tumor antigen or immune cell-mediated tumor destruction.

Abstract: A method is provided herein to increase an immune response to an antigen. The method includes administering an agent that inhibits extracellular adenosine or inhibits adenosine receptors. Also disclosed are methods to increase the efficacy of a vaccine and to increase an immune response to a tumor antigen or immune cell-mediated tumor destruction.

Abstract: A method is provided herein to increase an immune response to an antigen. The method includes administering an agent that inhibits extracellular adenosine or inhibits adenosine receptors. Also disclosed are methods to increase the efficacy of a vaccine and to increase an immune response to a tumor antigen or immune cell-mediated tumor destruction.

Abstract: The invention includes methods of treating, preventing, or limiting obesity or weight gain, or reducing or suppressing appetite, by the administration of A2A adenosine receptor pathway agonists. The A2AR pathway agonists may be administered in conjunction with a therapeutic agent having a side effect of weight gain, in order to prevent or limit that weight gain. In some instances, the A2AR pathway agonist is administered as a sleeping pill, and in other instances the A2AR pathway agonist is administered in a non-drowsy formulation.

Abstract: Disclosed herein are methods and compositions for expanding T-regulatory cells (“Treg” cells), resulting in “conditioned Treg cells.” Also disclosed herein are methods and compositions useful for modulating an autoimmune reaction and for treating or ameliorating immune-related diseases, disorders and conditions using the conditioned Treg cells.

Abstract: In the past, adoptive immunotherapy often failed because the transferred immune cells were inactive in vivo. This disclosure provides a method of producing immune cells that are highly active in vivo. The immune cells may be expanded in vitro in the presence of an adenosine receptor agonist or an antisense nucleic acid that downregulates expression of an adenosine receptor, for example. The immune cells may be tumor-infiltrating lymphocytes (TIL), cytotoxic T lymphocytes (CTL), natural killer (NK) cells, or lymphokine-activated killer (LAK) cells, for example. The methods described herein may be used to treat a number of diseases including cancer, infectious diseases, and immunodeficiencies.

Abstract: According to one aspect of the present invention, an apparatus includes a surface and a first array. The surface emits radiation, and the first array is arranged over the surface and arranged to provide cooling to the surface, the first array including a plurality of TECs. At least a first sensing arrangement is substantially integrated with the first array, wherein the first sensing arrangement is arranged to make a non-contact measurement associated with the surface. The apparatus also includes a controller arranged to obtain the non-contact measurement and to use the non-contact measurement to control the cooling provided by the first array.

Abstract: A method is provided herein to increase an immune response to an antigen. The method includes administering an agent that inhibits extracellular adenosine or inhibits adenosine receptors. Also disclosed are methods to increase the efficacy of a vaccine and to increase an immune response to a tumor antigen or immune cell-mediated tumor destruction.

Abstract: A method is provided herein to increase an immune response to an antigen. The method includes administering an agent that inhibits extracellular adenosine or inhibits adenosine receptors. Also disclosed are methods to increase the efficacy of a vaccine and to increase an immune response to a tumor antigen or immune cell-mediated tumor destruction.

Abstract: The invention includes methods of treating, preventing, or limiting obesity or weight gain, or reducing or suppressing appetite, by the administration of A2A adenosine receptor pathway agonists. The A2AR pathway agonists may be administered in conjunction with a therapeutic agent having a side effect of weight gain, in order to prevent or limit that weight gain. In some instances, the A2AR pathway agonist is administered as a sleeping pill, and in other instances the A2AR pathway agonist is administered in a non-drowsy formulation.

Abstract: Gel for radiation dosimeter including a gel part (A) and a gel part (B) that become cloudy when exposed to a fixed dose or more, wherein said gel part (A) exposed to more than a specified dose above the fixed dose maintains a cloudy state regardless of the decrease in external temperature; and said gel part (B) exposed to less than the specified dose above the fixed dose changes gradually from a cloudy state into a transparent state according to the decrease in external temperature.

Abstract: A method of producing high concentrated 99mTc solution has the steps of dissolving 99MoO3 pellet with alkali solution; extracting 99mTc from the dissolved solution with ketone type organic solvent; separating an ketone type organic phase containing 99mTc and an aqueous phase; adsorbing and concentrating the separated ketone type organic phase containing 99mTc after removing impurities, through a basic alumina column for impurity removal and an acidic alumina column for adsorption and concentration connected continuously; and eluting 99mTc from the acidic alumina column to which 99mTc is adsorbed by physiological saline, wherein the alkali solution is 6M-NaOH solution or 6M-KOH solution.

Abstract: According to one aspect of the present invention, an apparatus includes a surface and a first array. The surface emits radiation, and the first array is arranged over the surface and arranged to provide cooling to the surface, the first array including a plurality of TECs. At least a first sensing arrangement is substantially integrated with the first array, wherein the first sensing arrangement is arranged to make a non-contact measurement associated with the surface. The apparatus also includes a controller arranged to obtain the non-contact measurement and to use the non-contact measurement to control the cooling provided by the first array.

Abstract: A method is provided herein to increase an immune response to an antigen. The method includes administering an agent that inhibits extracellular adenosine or inhibits adenosine receptors. Also disclosed are methods to increase the efficacy of a vaccine and to increase an immune response to a tumor antigen or immune cell-mediated tumor destruction.

Abstract: Gel for radiation dosimeter including a gel part (A) and a gel part (B) that become cloudy when exposed to a fixed dose or more, wherein said gel part (A) exposed to more than a specified dose above the fixed dose maintains a cloudy state regardless of the decrease in external temperature; and said gel part (B) exposed to less than the specified dose above the fixed dose changes gradually from a cloudy state into a transparent state according to the decrease in external temperature.